Biosensors that measure glucose are now available without a prescription. Wearing one burst my wellness bubble in ways I wasn ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

If a patient receives a continuous glucose monitor device through their medical benefit, they may be more adherent and may ...

DexCom ( DXCM -1.08%) is not a stock that investors should be rushing to sell. It has a few different opportunities to ...

Continuous Glucose Monitoring (CGM) Systems Market The increasing incidence of diabetes and the detection of patient's blood glucose levels are raising the demand for continuous global monitoring ...

Living with Type 1 diabetes presents unique challenges, especially for athletes who push their bodies to the limit. Yet, ...

St. Louis-based diabetes treatment startup Aegis Digital Health is nearing $1 million in its latest funding round and seeing ...

With the company's market cap of $28 billion today, it's important to recognize that DexCom (NASDAQ: DXCM) is already one of ...

The implementation of an inpatient continuous glucose monitoring policy was accurate and feasible among patients and nurses. Implementation of continuous glucose monitoring (CGM) in the hospital ...

As part of its ongoing exploration of vocal biomarkers and the role they can play in enhancing health outcomes, Klick Labs ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in ...